NCT04882943

Brief Summary

Chronic cough (TC), defined by a duration exceeding 8 weeks, is a particularly frequent symptom with a prevalence observed at 9.6% 1. Chronic cough is the cause of a major handicap for patients with a impact on their quality of life 2. Although CT is common, management is often delicate and complex. In studies, asthma, gastroesophageal reflux disease, posterior flushing, rhino-sinusitis, or taking tussigenic medications are common causes of chronic coughs. However, chronic refractory or unexplained cough, which corresponds to cough for which no cause has been found or the treatments directed against the cause of the cough have not made it possible to resolve the cough, is a real problem in practice. nick3. There is currently no prospective data in France on the characteristics of chronic cough (etiologies, response to treatment) and the percentage of refractory cough. The aim of the study is to constitute a French prospective multicenter hospital cohort of chronic cough patients in order to identify, for the first time in France in a prospective and multicenter manner, the frequency of patients with refractory cough among chronic cough patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
178

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2021

Longer than P75 for all trials

Geographic Reach
1 country

6 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 6, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 12, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

June 22, 2021

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 25, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 2, 2026

Completed
Last Updated

April 14, 2026

Status Verified

April 1, 2026

Enrollment Period

4.4 years

First QC Date

May 6, 2021

Last Update Submit

April 8, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • French prospective multicenter hospital cohort of chronic cough patients (requency of patients with unexplained or refractory chronic cough (URCC)

    set up a French prospective multicenter hospital cohort of chronic cough patients in order to identify the frequency of patients with unexplained or refractory chronic cough (URCC) for the first time in France

    24 months

Study Arms (1)

patients with unexplained or refractory chronic cough

Patients with cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough)

Other: questionnaires

Interventions

Quality of life questionnaires

patients with unexplained or refractory chronic cough

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

chronic cough patients

You may qualify if:

  • Age ≥18 years old
  • Consultation motivated by cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough)
  • Patient covered by a National Health Insurance

You may not qualify if:

  • Active smoker or recent smoking cessation (within the past 6 months)
  • Intake of medications causing cough (the patient can be included 4 weeks after treatment discontinuation if cough persists)
  • Pregnant or breast-feeding women
  • Upper or lower respiratory tract infection within the past 4 weeks
  • Active lung disease (such as interstitial lung disease, lung cancer, abnormal dilation of the bronchi).
  • History of chronic bronchitis.
  • Current treatment with an angiotensin converting enzyme (ACE) inhibitor
  • History of cancer within the past 5 years or active cancer (excluding cutaneous squamous-cell carcinoma).
  • Person not fluent in French
  • Adult not able to express his/her consent verbally
  • Patient refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

CHU de Besançon

Besançon, France

Location

CHU de Bordeaux

Bordeaux, France

Location

CH de Libourne

Libourne, France

Location

AP-HP Bichat

Paris, France

Location

UHToulouse

Toulouse, 31059, France

Location

CHU de Tours

Tours, France

Location

Related Publications (1)

  • Guilleminault L, Dupin C, Portel L, Zysman M, Flament T, Roux P, Costa N, Mounie M. The Healthcare Resource Utilization of Patients with Refractory Chronic Cough Compared to Those with Non-Refractory Chronic Cough. Lung. 2025 Oct 4;203(1):97. doi: 10.1007/s00408-025-00853-z.

MeSH Terms

Conditions

Chronic Cough

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

CoughRespiration DisordersRespiratory Tract DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Laurent GUILLEMINAULT

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 6, 2021

First Posted

May 12, 2021

Study Start

June 22, 2021

Primary Completion

November 25, 2025

Study Completion

April 2, 2026

Last Updated

April 14, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations